U.S. FDA finds commonly used asthma drug impacts the brain [Video]

U.S. government researchers have found that a widely prescribed asthma drug originally sold by Merck & Co MRK.N may be linked to serious mental health problems for some patients, according to a scientific presentation reviewed by Reuters.

The researchers found that the drug, sold under the brand name Singulair and generically as montelukast, attaches to multiple brain receptors critical to psychiatric functioning.

• The information you need to know, sent directly to you: Download the CTV News App

Singulair was a blockbuster product for Merck after its launch in 1998, offering relief in a pill as an alternative to an inhaler. In early advertising, the company said the side effects were so benign that they were “similar to a sugar pill,” while the label said any distribution in the brain was “minimal.” Generic versions are still prescribed to millions of adults and children every year.

But by 2019, thousands of reports …